Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

The U.S. Food and Drug Administration (FDA) recently approved the use of Darzalex Faspro (daratumumab and hyaluronidase-fihj) ...

The investigational oral therapy KTX-1001, also known as gintemetostat, is catching interest as a potential treatment for a subgroup of patients with multiple myeloma, as an expert explained in a ...

UK Myeloma expert from Oxford, Professor Karthik Ramasamy, Clinical Director, SACT Clinical Reference Group for GenesisCare, based at their centre in Oxford, is leading the SECURE study, one of ...

When you have multiple myeloma, infections are something you’ll need to watch out for. The disease and its treatment make infections more likely. If you get an infection, it’s also more likely to get ...

In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) For over half a ...

My blood work showed that I was slightly low in vitamin D, so my doctor recommended that I take a supplement. My pharmacist ...

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD. While teclistamab originally received ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) began as therapies for type 2 diabetes but have become a breakthrough therapy for obesity, redefining its treatment and broader metabolic landscape ...

Researchers have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...

Monoclonal B-cell lymphocytosis (MBL) is when you have a high number of identical B cells, under 5,000 per microliter, for at least 3 months. It usually causes no symptoms or need for active treatment ...